4th Quarter - Amendment

CSL BEHRING LLC for CSL BEHRING LLC

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 8, 2015 $170,000 Replaced
4th Quarter - Amendment (this page) Jan 8, 2015 $170,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

LobbyistCovered position, as disclosed
BRIAN R. BULLARD Sr. Manager, Federal Government Affairs
PATRICK COLLINS Director, Healthcare Policy & External Affairs
DENNIS JACKMAN Senior Vice President, Healthcare Policy & External Affairs

Contacted: Treasury, Dept of; SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2315 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.